Ovarian Cancer and Immunotherapy

October 8, 2021, 3:40 pm -
4:15 pm
New potential in gynecologic cancers

Session Description

Globally, ovarian cancer is diagnosed in an estimated 300,000 women each year—and another 570,000 are diagnosed with cervical cancer and 382,000 with uterine (endometrial) cancer. While significant advances have been made in surgical and chemo-based treatments for ovarian cancer, the survival rates have only modestly improved. Immunotherapy for ovarian cancer shows tremendous potential for addressing this devastating disease. In this session, Dr. Dmitriy Zamarin, medical oncologist at Memorial Sloan Kettering Cancer Center, will discuss details of immunotherapy clinical trials in ovarian cancer currently underway and take your questions about new treatments in gynecologic cancers.


Dmitriy Zamarin, M.D., Ph.D.

Memorial Sloan Kettering Cancer Center

Dr. Dmitriy Zamarin is a medical oncologist at Memorial Sloan Kettering Cancer Center who specializes in the care of women with gynecologic cancers, including cervical, ovarian, and endometrial cancers. He works closely with a multidisciplinary team of medical oncologists, surgeons, and radiation oncologists with a goal to deliver the highest quality care for patients and their families. Dr. Zamarin’s clinical and laboratory research is focused on the development of novel ways to use the immune system to treat cancer, and he is involved in clinical trials evaluating novel immunotherapy drugs in patients with cancer. In addition, he has a special interest in genetically engineered oncolytic viruses, an emerging class of immune therapeutic drugs that have shown significant clinical promise in recent years. By manipulating the oncolytic viruses and the immune system, Dr. Zamarin is exploring different ways to enhance the immune recognition of tumors and to develop novel treatment strategies that would be applicable to different cancer types.